SG11201707527YA - Inhibitors of hepatitis c virus polymerase - Google Patents
Inhibitors of hepatitis c virus polymeraseInfo
- Publication number
- SG11201707527YA SG11201707527YA SG11201707527YA SG11201707527YA SG11201707527YA SG 11201707527Y A SG11201707527Y A SG 11201707527YA SG 11201707527Y A SG11201707527Y A SG 11201707527YA SG 11201707527Y A SG11201707527Y A SG 11201707527YA SG 11201707527Y A SG11201707527Y A SG 11201707527YA
- Authority
- SG
- Singapore
- Prior art keywords
- hepatitis
- inhibitors
- virus polymerase
- polymerase
- virus
- Prior art date
Links
- 241000711549 Hepacivirus C Species 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562136857P | 2015-03-23 | 2015-03-23 | |
| PCT/US2016/023664 WO2016154241A1 (en) | 2015-03-23 | 2016-03-23 | Inhibitors of hepatitis c virus polymerase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707527YA true SG11201707527YA (en) | 2017-10-30 |
Family
ID=55759915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707527YA SG11201707527YA (en) | 2015-03-23 | 2016-03-23 | Inhibitors of hepatitis c virus polymerase |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10464914B2 (https=) |
| EP (1) | EP3274340B1 (https=) |
| JP (1) | JP6741747B2 (https=) |
| KR (1) | KR20170137113A (https=) |
| CN (1) | CN107567442B (https=) |
| AU (1) | AU2016235246B2 (https=) |
| CA (1) | CA2979555C (https=) |
| DK (1) | DK3274340T3 (https=) |
| EA (1) | EA033622B1 (https=) |
| ES (1) | ES2748974T3 (https=) |
| IL (1) | IL254243B (https=) |
| MX (1) | MX379015B (https=) |
| NZ (1) | NZ735093A (https=) |
| PH (1) | PH12017501687A1 (https=) |
| PL (1) | PL3274340T3 (https=) |
| SG (1) | SG11201707527YA (https=) |
| TW (1) | TWI731854B (https=) |
| WO (1) | WO2016154241A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI731854B (zh) * | 2015-03-23 | 2021-07-01 | 美商共結晶製藥公司 | Ｃ型肝炎病毒聚合酶之抑制劑 |
| MX2020011912A (es) * | 2018-05-09 | 2021-01-29 | Cocrystal Pharma Inc | Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc). |
| CN112745216A (zh) * | 2019-10-30 | 2021-05-04 | 常州锐博生物科技有限公司 | 一种4-溴甲基苯甲酸甲酯及其衍生物的制备方法 |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
| CN114181187A (zh) * | 2021-11-24 | 2022-03-15 | 上海应用技术大学 | 一种4-甲磺酰胺基丁酰胺化合物的制备方法 |
| CN116283512B (zh) * | 2023-02-24 | 2025-04-25 | 博诺康源(北京)药业科技有限公司 | 一种合成维兰特罗及其盐的方法 |
| WO2025111414A1 (en) * | 2023-11-21 | 2025-05-30 | Katholieke Universiteit Leuven | Trpm3-modulating benzofuran derivatives |
| CN119350612B (zh) * | 2024-12-24 | 2025-10-24 | 浙江爱索拓标记医药科技有限公司 | 一种放射性同位素碳-14标记聚乙二醇单甲醚的合成方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ305166A (en) | 1995-03-20 | 1998-12-23 | Lilly Co Eli | 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6887877B2 (en) | 2001-06-11 | 2005-05-03 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
| CN101624391A (zh) | 2001-06-11 | 2010-01-13 | 病毒化学医药公司 | 用作黄病毒感染抗病毒剂的噻吩衍生物 |
| EP1321463B1 (en) | 2001-12-21 | 2007-08-08 | Virochem Pharma Inc. | Thiazole derivatives and their use for the treatment or prevention of Flavivirus infections |
| CN1731993A (zh) * | 2002-11-01 | 2006-02-08 | 维洛药品公司 | 苯并呋喃化合物、组合物以及治疗和预防丙型肝炎病毒感染及相关疾病的方法 |
| US7402608B2 (en) | 2002-12-10 | 2008-07-22 | Virochem Pharma Inc. | Compounds and methods for the treatment or prevention of Flavivirus infections |
| JP4926403B2 (ja) | 2002-12-10 | 2012-05-09 | ヴァイロケム ファーマ インコーポレイテッド | フラビウイルス感染の処置もしくは予防のための化合物および方法 |
| AU2003291886A1 (en) | 2002-12-10 | 2004-06-30 | Virochem Pharma Inc. | Thiophenederivatives for the treatment of flavivirus infections |
| EP1753750A1 (en) | 2004-05-20 | 2007-02-21 | Sugen, Inc. | Thiophene heteroaryl amines |
| DE102004061746A1 (de) | 2004-12-22 | 2006-07-06 | Bayer Healthcare Ag | Alkinyl-substituierte Thiophene |
| BRPI0610283A2 (pt) | 2005-05-13 | 2010-10-19 | Virochem Pharma Inc | composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica |
| PE20070814A1 (es) | 2005-12-22 | 2007-08-16 | Smithkline Beecham Corp | Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv) |
| WO2008017688A1 (en) | 2006-08-11 | 2008-02-14 | Smithkline Beecham Corporation | 2-carboxy thiophene derivatives as anti-viral agents |
| TW200815384A (en) | 2006-08-25 | 2008-04-01 | Viropharma Inc | Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein |
| WO2008043791A2 (en) | 2006-10-13 | 2008-04-17 | Smithkline Beecham Corporation | Thiophene derivatives for treating hepatitis c |
| CA2670260A1 (en) | 2006-11-15 | 2008-05-22 | Virochem Pharma Inc. | Thiophene analogues for the treatment or prevention of flavivirus infections |
| EP2086966B1 (en) | 2006-11-17 | 2011-09-14 | GlaxoSmithKline LLC | 2-carboxy thiophene derivatives as anti viral agents |
| GB0707092D0 (en) | 2007-04-12 | 2007-05-23 | Smithkline Beecham Corp | Compounds |
| GB0712393D0 (en) | 2007-06-26 | 2007-08-01 | Smithkline Beecham Corp | Compounds |
| GB0718435D0 (en) * | 2007-09-21 | 2007-10-31 | Northern Health And Social Car | Wpund care formulation |
| EP2245023B1 (en) | 2008-02-14 | 2011-12-28 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| WO2009137500A1 (en) * | 2008-05-05 | 2009-11-12 | Wyeth | 6-substituted benzofuran compounds to treat infection with hepatitis c virus |
| WO2011106929A1 (en) | 2010-03-02 | 2011-09-09 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus ns5b polymerase |
| AR080433A1 (es) * | 2010-03-02 | 2012-04-11 | Merck Sharp & Dohme | Derivados de benzofurancarboxamidas utiles para tratar o prevenir infecciones por vhc y composiciones farmaceuticas que los contienen. |
| AR082453A1 (es) * | 2010-04-21 | 2012-12-12 | Novartis Ag | Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos |
| AU2011329485A1 (en) * | 2010-11-18 | 2013-04-18 | Glaxo Group Limited | Compounds |
| EP2651906A4 (en) | 2010-12-17 | 2014-06-25 | Cocrystal Discovery Inc | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE |
| WO2014055142A1 (en) | 2012-06-20 | 2014-04-10 | Cocrystal Discovery, Inc. | Inhibitors of hepatitis c virus polymerase |
| TWI731854B (zh) * | 2015-03-23 | 2021-07-01 | 美商共結晶製藥公司 | Ｃ型肝炎病毒聚合酶之抑制劑 |
-
2016
- 2016-03-21 TW TW105108618A patent/TWI731854B/zh not_active IP Right Cessation
- 2016-03-23 EA EA201792094A patent/EA033622B1/ru not_active IP Right Cessation
- 2016-03-23 SG SG11201707527YA patent/SG11201707527YA/en unknown
- 2016-03-23 KR KR1020177030184A patent/KR20170137113A/ko not_active Abandoned
- 2016-03-23 US US15/556,653 patent/US10464914B2/en active Active
- 2016-03-23 CN CN201680017709.XA patent/CN107567442B/zh active Active
- 2016-03-23 MX MX2017012238A patent/MX379015B/es unknown
- 2016-03-23 NZ NZ735093A patent/NZ735093A/en not_active IP Right Cessation
- 2016-03-23 JP JP2018501147A patent/JP6741747B2/ja active Active
- 2016-03-23 WO PCT/US2016/023664 patent/WO2016154241A1/en not_active Ceased
- 2016-03-23 CA CA2979555A patent/CA2979555C/en active Active
- 2016-03-23 DK DK16717211.3T patent/DK3274340T3/da active
- 2016-03-23 AU AU2016235246A patent/AU2016235246B2/en not_active Ceased
- 2016-03-23 ES ES16717211T patent/ES2748974T3/es active Active
- 2016-03-23 EP EP16717211.3A patent/EP3274340B1/en active Active
- 2016-03-23 PL PL16717211T patent/PL3274340T3/pl unknown
-
2017
- 2017-08-31 IL IL254243A patent/IL254243B/en active IP Right Grant
- 2017-09-14 PH PH12017501687A patent/PH12017501687A1/en unknown
-
2019
- 2019-09-25 US US16/582,468 patent/US10947210B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018512453A (ja) | 2018-05-17 |
| EA033622B1 (ru) | 2019-11-11 |
| JP6741747B2 (ja) | 2020-08-19 |
| CA2979555A1 (en) | 2016-09-29 |
| CN107567442A (zh) | 2018-01-09 |
| KR20170137113A (ko) | 2017-12-12 |
| CA2979555C (en) | 2023-12-19 |
| IL254243A0 (en) | 2017-10-31 |
| US10947210B2 (en) | 2021-03-16 |
| PL3274340T3 (pl) | 2020-01-31 |
| HK1243703A1 (zh) | 2018-07-20 |
| AU2016235246B2 (en) | 2020-12-10 |
| DK3274340T3 (da) | 2019-10-07 |
| EP3274340A1 (en) | 2018-01-31 |
| IL254243B (en) | 2020-10-29 |
| TWI731854B (zh) | 2021-07-01 |
| TW201643147A (zh) | 2016-12-16 |
| PH12017501687A1 (en) | 2018-03-19 |
| ES2748974T3 (es) | 2020-03-18 |
| US20200255393A1 (en) | 2020-08-13 |
| HK1249514A1 (en) | 2018-11-02 |
| EP3274340B1 (en) | 2019-07-17 |
| US20180050998A1 (en) | 2018-02-22 |
| US10464914B2 (en) | 2019-11-05 |
| MX379015B (es) | 2025-03-10 |
| MX2017012238A (es) | 2018-02-15 |
| AU2016235246A1 (en) | 2017-09-21 |
| BR112017020168A2 (pt) | 2018-06-05 |
| NZ735093A (en) | 2022-09-30 |
| WO2016154241A1 (en) | 2016-09-29 |
| EA201792094A1 (ru) | 2018-03-30 |
| CN107567442B (zh) | 2021-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL280459A (en) | Phosphoramidates for the treatment of hepatitis b virus | |
| IL251450A0 (en) | Preparations and methods for silencing hepatitis b virus gene expression | |
| SG11201707663SA (en) | Lyophilization of rna | |
| SG10202007323VA (en) | Hepatitis b virus (hbv) irna compositions and methods of use thereof | |
| SG11201803474UA (en) | Vaccines against hepatitis b virus | |
| IL254243A0 (en) | Hepatitis C virus polymerase inhibitors. | |
| IL247364A0 (en) | c5a inhibitors for the treatment of viral pneumonia | |
| SG10201913958QA (en) | Modulation of hepatitis b virus replication | |
| IL249660A0 (en) | Methods for treating hepatitis b virus and hepatitis d virus infections | |
| PL3137078T3 (pl) | Leczenie zakażenia wirusem zapalenia wątroby typu delta | |
| GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL248318A0 (en) | Selective inhibitors that have an effect on the hepatitis virus type c | |
| GB201402169D0 (en) | Viral inhibitors | |
| TH1601001227A (th) | ตัวยับยั้ง hcv โพลีเมอเรส | |
| HK1234102A1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| GB201520019D0 (en) | The genome and self-evolution of AI | |
| GB201522013D0 (en) | Virus | |
| GB201416054D0 (en) | Chemotherapy of viruses | |
| GB201516936D0 (en) | Virus | |
| GB201507419D0 (en) | Virus | |
| GB201403369D0 (en) | RNA Virus induced gene expression |